Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05254067 · ClinicalTrials.gov registry record
Enterprise 2 Vascular Reconstruction Device
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 10
- Enrollment target
NCT05254067: Completed study, sponsored by Methodist Health System.
NCT05254067 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05254067 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The primary objective of this study is to collect data regarding the effectiveness of using the Enterprise 2 Reconstruction Device in successfully embolizing intracranial aneurysms with wide neck configuration.
Primary Outcome
Prior Observation studies have noted in other stents, that over time, a stent may migrate from its original location, given the flow dynamics and potentially from stent under-sizing. This could potentially disrupt flow through the artery, or even uncover the aneurysm, openining, potentially allowing outflow of embolization coils.
Interventions
- DEVICE Codman Enterprise 2 Vascular Reconstruction Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2026-01-05 |
What the finished NCT05254067 record still lists
NCT05254067 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Codman Enterprise 2 Vascular Reconstruction Device is the first listed.
NCT05254067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05254067 about?
NCT05254067 is a clinical study titled "Enterprise 2 Vascular Reconstruction Device". The primary objective of this study is to collect data regarding the effectiveness of using the Enterprise 2 Reconstruction Device in successfully embolizing intracranial aneurysms with wide neck configuration.
What is the current status of trial NCT05254067?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2017-02-28. Estimated completion is 2026-01-05.
What interventions are being tested in trial NCT05254067?
The interventions under investigation include: Codman Enterprise 2 Vascular Reconstruction Device (DEVICE).
Who is sponsoring clinical trial NCT05254067?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI